In vivo and in vitro distribution of type 5 and fiber-modified oncolytic adenoviruses in human blood compartments

Annals of Medicine

Volumn 43, Issue 2, 2011, Pages 151-163

  Escutenaire, Sophie ^a,b   Cerullo, Vincenzo ^a,b   Diaconu, Iulia ^a,b   Ahtiainen, Laura ^a,b   Hannuksela, Pãivi ^a,b   Oksanen, Minna ^a,b   Haavisto, Elina ^d   Karioja Kallio, Aila ^d   Holm, Sirkka Liisa ^a,b   Kangasniemi, Lotta ^d   Ribacka, Camilla ^a,b   Kauppinen, Satu ^c   Joensuu, Timo ^c   Petteri Arstila, T ^e   Pesonen, Sari ^a,b   Kanerva, Anna ^a,b   Hemminki, Akseli ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c International Comprehensive Cancer Center Docrates   (Finland)

^d Oncos Therapeutics Ltd   (Finland)

^e UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Blood; gene therapy; oncolytic viruses; pharmacokinetics

Indexed keywords

ARTICLE; BLOOD CELL; BLOOD CLOT; CANCER PATIENT; CELL COMPARTMENTALIZATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ERYTHROCYTE; GRANULOCYTE; HUMAN; HUMAN ADENOVIRUS 5; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MONOCYTE; NEUTROPHIL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PREVALENCE; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; VIRAL CLEARANCE; VIRUS CAPSID; VIRUS LOAD; VIRUS PARTICLE; VIRUS REPLICATION;

ADENOVIRIDAE; BLOOD COAGULATION; BLOOD PLATELETS; ERYTHROCYTES; GRANULOCYTES; HUMANS; MONOCYTES; NEOPLASMS; NEUTROPHILS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; T-LYMPHOCYTES, CYTOTOXIC; VIRUS REPLICATION;

EID: 79951569626     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2010.538079     Document Type: Article

References (43)

1. Senac JS, Doronin K, Russell SJ, Jelinek DF, Greipp PR, Barry MA. Infection and killing of multiple myeloma by adenoviruses. Hum Gene Ther. 2010;21:179-90.
2. Yamamoto M, Curiel D T. Current issues and future directions of oncolytic adenoviruses. Mol Ther. 2010;18: 243-50.
3. Lyons M, Onion D, Green NK, Aslan K, Rajaratnam R, Bazan-Peregrino M, et al. Adenovirus type 5 interactions with human blood cells may compromise systemic delivery. Mol Ther. 2006;14:118-28. (Pubitemid 44191831)
4. Carlisle RC, Di Y, Cerny AM, Sonnen AF, Sim RB, Green NK, et al. Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood. 2009;113: 1909-18.
5. Othman M, Labelle A, Mazzetti I, Elbatarny HS, Lillicrap D. Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance. Blood. 2007;109:2832-9. (Pubitemid 46482078)
6. Baker AH. Shedding light on tumor targeting by adenovirus. Mol Ther. 2007;15:841-2. (Pubitemid 46621641)
7. Worgall S, Leopold PL, Wolff G, Ferris B, Van Roijen N, Crystal RG. Role of alveolar macrophages in rapid elimination of adenovirus vectors administered to the epithelial surface of the respiratory tract. Hum Gene Ther. 1997;8: 1675-84. (Pubitemid 28031586)
8. Shimony N, Elkin G, Kolodkin-Gal D, Krasny L, Urieli-Shoval S, Haviv YS. Analysis of adenoviral attachment to human platelets. Virol J. 2009;6:25.
9. Perlman J, Gibson C, Pounds SB, Gu Z, Bankowski MJ, Hayden RT. Quantitative real-time PCR detection of adeno-virus in clinical blood specimens: a comparison of plasma, whole blood and peripheral blood mononuclear cells. J Clin Virol. 2007;40:295-300. (Pubitemid 350152002)
10. Shike H, Shimizu C, Kanegaye J, Foley JL, Burns JC. Quan-titation of adenovirus genome during acute infection in normal children. Pediatr Infect Dis J. 2005;24:29-33. (Pubitemid 40353313)
11. Cerullo V, Pesonen S, Diaconu I, Escutenaire S, Arstila PT, Ugolini M, et al. Oncolytic adenovirus coding for granulo-cyte macrophage colony-stimulating factor induces antitu-moral immunity in cancer patients. Cancer Res. 2010;70: 4297-309.
12. Cichon G, Schmidt HH, Benhidjeb T, Loser P, Ziemer S, Haas R, et al. Intravenous administration of recombinant adenoviruses causes thrombocytopenia, anemia and eryth-roblastosis in rabbits. J Gene Med. 1999;1:360-71. (Pubitemid 129631136)
13. Lozier JN, Csako G, Mondoro TH, Krizek DM, Metzger ME, Costello R, et al. Toxicity of a fi rst-generation adenoviral vector in rhesus macaques. Hum Gene Ther. 2002;13: 113-24. (Pubitemid 34075175)
14. Varnavski AN, Calcedo R, Bove M, Gao G, Wilson JM. Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and pre-immunized mice. Gene Ther. 2005;12:427-36. (Pubitemid 40394295)
15. Pesonen S, Nokisalmi P, Escutenaire S, Sarkioja M, Raki M, Cerullo V, et al. Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors. Gene Ther. 2010; 17:892-904.
16. Nokisalmi P, Pesonen S, Escutenaire S, Sarkioja M, Raki M, Cerullo V, et al. Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors. Clin Cancer Res. 2010;16:3035-43.
17. Flomenberg P, Gutierrez E, Piaskowski V, Casper J T. Detection of adenovirus DNA in peripheral blood mononu-clear cells by polymerase chain reaction assay. J Med Virol. 1997;51:182-8. (Pubitemid 27157798)
18. Durepaire N, Rogez JP, Verdier M, Rogez S, Weinbreck P, Denis F. Detection of adenovirus DNA by polymerase chain reaction in peripheral blood lymphocytes from HIV-infected patients and a control group: preliminary results. J Acquir Immune Defi c Syndr Hum Retrovirol. 1997;14: 189-90. (Pubitemid 27091808)
19. Qiao J, Kottke T, Willmon C, Galivo F, Wongthida P, Diaz RM, et al. Purging metastases in lymphoid organs using a combination of antigen-nonspecifi c adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nat Med. 2008; 14:37-44.
20. Ilett EJ, Prestwich RJ, Kottke T, Errington F, Thompson JM, Harrington KJ, et al. Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity. Gene Ther. 2009;16:689-99.
21. Yotnda P, Savoldo B, Charlet-Berguerand N, Rooney C, Brenner M. Targeted delivery of adenoviral vectors by cytotoxic T cells. Blood. 2004;104:2272-80. (Pubitemid 39331823)
22. Pesonen S, Cerullo V, Escutenaire S, Raki M, Kangasniemi L, Karli E, et al., editors. Treatment of cancer patients with integrin-targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF. Paper presented at the Annual Meeting of American Society of Gene and Cell Therapy; 19-22 May 2010; Washington, DC, USA.
23. Koski A, Kangasniemi L, Escutenaire S, Pesonen S, Cerullo V, Diaconu I, et al. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther. 2010;18:1874-84.
24. Alvarez-Lafuente R, Garcia-Montojo M, De Las Heras V, Bartolome M, Arroyo R. Interferon-beta treatment and active replication of the JC virus in relapsing-remitting multiple sclerosis patients. Eur J Neurol. 2007;14:233-6. (Pubitemid 46148315)
25. Suzuki K, Fueyo J, Krasnykh V, Reynolds PN, Curiel DT, Alemany R. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res. 2001;7:120-6. (Pubitemid 32110214)
26. Bauerschmitz GJ, Guse K, Kanerva A, Menzel A, Herrmann I, Desmond RA, et al. Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells. Mol Ther. 2006;14:164-74. (Pubitemid 43964496)
27. Rojas JJ, Cascallo M, Guedan S, Gros A, Martinez-Quintanilla J, Hemminki A, et al. A modifi ed E2F-1 promoter improves the effi cacy to toxicity ratio of oncolytic adenoviruses. Gene Ther. 2009;16:1441-51.
28. Reid T, Galanis E, Abbruzzese J, Sze D, Wein LM, Andrews J, et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res. 2002;62:6070-9. (Pubitemid 35244455)
29. DeWeese TL, van der Poel H, Li S, Mikhak B, Drew R, Goemann M, et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 2001;61:7464-72. (Pubitemid 32995035)
30. Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummersen L, et al. A phase I trial of intravenous CG7870, a replication-selective, prostate-specifi c antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther. 2006; 14:107-17. (Pubitemid 43899483)
31. Reinhold MI, Lindberg FP, Plas D, Reynolds S, Peters MG, Brown EJ. In vivo expression of alternatively spliced forms of integrin-associated protein (CD47). J Cell Sci. 1995; 108:3419-25.
32. Coulombel L, Auffray I, Gaugler MH, Rosemblatt M. Expression and function of integrins on hematopoietic progenitor cells. Acta Haematol. 1997;97:13-21. (Pubitemid 26413944)
33. Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G, et al. An adenovirus vector with genetically modifi ed fi bers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol. 1998;72:9706-13. (Pubitemid 28520834)
34. Kanerva A, Mikheeva GV, Krasnykh V, Coolidge CJ, Lam JT, Mahasreshti PJ, et al. Targeting adenovirus to the serotype 3 receptor increases gene transfer effi ciency to ovarian cancer cells. Clin Cancer Res. 2002;8:275-80. (Pubitemid 34101488)
35. Kanerva A, Wang M, Bauerschmitz GJ, Lam JT, Desmond RA, Bhoola SM, et al. Gene transfer to ovarian cancer versus normal tissues with fi ber-modifi ed adenoviruses. Mol Ther. 2002;5:695-704. (Pubitemid 34619062)
36. Willmon C, Harrington K, Kottke T, Prestwich R, Melcher A, Vile R. Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. Mol Ther. 2009;17:1667-76.
37. Leon RP, Hedlund T, Meech SJ, Li S, Schaack J, Hunger SP, et al. Adenoviral-mediated gene transfer in lymphocytes. Proc Natl Acad Sci USA. 1998;95:13159-64. (Pubitemid 28509541)
38. Cotter MJ, Zaiss AK, Muruve DA. Neutrophils interact with adenovirus vectors via Fc receptors and complement receptor 1. J Virol. 2005;79:14622-31. (Pubitemid 41636261)
39. Schierer S, Hesse A, Muller I, Kampgen E, Curiel DT, Schuler G, et al. Modulation of viability and maturation of human monocyte-derived dendritic cells by oncolytic adenoviruses. Int J Cancer. 2008;122:219-29. (Pubitemid 350209999)
40. Short JJ, Pereboev AV, Kawakami Y, Vasu C, Holterman MJ, Curiel D T. Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptors. Virology. 2004;322:349-59. (Pubitemid 38521149)
41. Short JJ, Vasu C, Holterman MJ, Curiel DT, Pereboev A. Members of adenovirus species B utilize CD80 and CD86 as cellular attachment receptors. Virus Res. 2006;122: 144-53. (Pubitemid 44740333)
42. Lavery D, Fu SM, Lufkin T, Chen-Kiang S. Productive infection of cultured human lymphoid cells by adenovirus. J Virol. 1987;61:1466-72. (Pubitemid 17069735)
43. Danielsson A, Elgue G, Nilsson BM, Nilsson B, Lambris JD, Totterman TH, et al. An ex vivo loop system models the toxicity and effi cacy of PEGylated and unmodifi ed adenovi-rus serotype 5 in whole human blood. Gene Ther. 2010; 17:752-62.